Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZFN-603 and ZFN-758 in HPV-infected CIN
NCT02800369Phase 1Unknown
- Sponsor
- Huazhong University of Science and Technology
- Start
- Dec 2016
- Primary completion
- Jun 2017
- Modality
- Gene Silencing, Zinc Finger Nucleases, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZFN-603 and ZFN-758 in cervical intraepithelial neoplasia (CIN), sponsored by Huazhong University of Science and Technology. Primary endpoint: Treatment related adverse events at 6 months. Status: unknown.
02
Drugs
ZFN-603ZFN-758
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT02800369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02800369.